The purpose of this research study is to test if a combination treatment of chimeric antigen receptor (CAR) T-cell therapy, Mosunetuzumab, and Polatuzumab Vedo…

Refractory Non-Hodgkin LymphomaRelapsed Non Hodgkin LymphomaAggressive Non-Hodgkin Lymphoma

~Estimated

~$10 – $7,500

Lazaros LekakisNCT05260957

Phase 1

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lym…

Lymphoma, Non-HodgkinRelapsed Non Hodgkin LymphomaRefractory B-Cell Non-Hodgkin Lymphoma+4 more

~Estimated

~$10 – $8,750

Caribou Biosciences, Inc.NCT04637763